Literature DB >> 9153436

Butorphanol (Stadol): a study in problems of current drug information and control.

M A Fisher1, S Glass.   

Abstract

Butorphanol (Stadol, Bristol-Meyers Squibb, Princeton, NJ) is a synthetically derived opiate. As a nasal spray, it was approved for release in 1991 and was subsequently promoted as a safe treatment for migraine. Since then, there have been numerous reports of problems with butorphanol similar to those of any narcotic, especially dependence-addiction and major psychological disturbances. These problems have been documented by the Food and Drug Administration, but the information can be obtained only through the Freedom of Information Act. The experience with butorphanol indicates the need for physicians to have additional sources of information about drugs than are presently available.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9153436     DOI: 10.1212/wnl.48.5.1156

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

Review 1.  Medication overuse headache: a focus on analgesics, ergot alkaloids and triptans.

Authors:  Z Katsarava; H C Diener; V Limmroth
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  [Gordian knot: medication overuse headache].

Authors:  Z Katsarava; G Fritsche
Journal:  Schmerz       Date:  2004-10       Impact factor: 1.107

Review 3.  Intranasal medications for the treatment of migraine and cluster headache.

Authors:  Alan M Rapoport; Marcelo E Bigal; Stewart J Tepper; Fred D Sheftell
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

4.  The pharmacological management of migraine, part 1: overview and abortive therapy.

Authors:  George Demaagd
Journal:  P T       Date:  2008-07

Review 5.  Newer formulations of the triptans: advances in migraine management.

Authors:  Jonathan Paul Gladstone; Marek Gawel
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Analgesic/abortive overuse and misuse in chronic daily headache.

Authors:  H C Diener; Z Katasarva
Journal:  Curr Pain Headache Rep       Date:  2001-12

7.  Successful conversion from butorphanol nasal spray to buprenorphine/naloxone using a low-dose regimen to assist with opioid tapering in the setting of chronic pain and migraine management in an older adult patient: A case report.

Authors:  Joshua MacAusland-Berg; Amy Wiebe; Radhika Marwah; Katelyn Halpape
Journal:  Can J Pain       Date:  2022-08-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.